oral glp-1 agonist for type 2 diabetes Lilly's Orforglipron Delivers in Phase III Trial Published: April 17, 2025 @AskDrShashank Eli Lilly's oral GLP-1 receptor agonist, orforglipron, demonstrated robust results in its first Phase III trial (ACHIEVE-1) How GLP-1 Receptor Agonists Evolved
Pay in 4 interest-free payments of $5.47 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22

:max_bytes(150000):strip_icc()/health-GettyImages-2025836701-ce3f5ccf0f98428e9d14abaeb07ba307.jpg)






















